The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
Open accessAbstract
The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has been granted authorization or approval in several countries for the treatment of patients with mild to moderate COVID‐19 at high risk of progression to severe disease and with no requirement for supplemental oxygen. Nirmatrelvir/ritonavir will be primarily administered outside the hospital setting as a 5‐day course oral treatment. The ritonavir component boosts plasma concentrations of nirmatrelvir through the potent and rapid inhibition of the key drug‐metabolizing enzyme cytochrome P450 (CYP) 3A4. Thus nirmatrelvir/ritonavir, even given as a short treatment course, has a high potential to cause harm from drug–drug interactions (DDIs) with other drugs metabolized through this pathway. Options for mitigating risk from DDIs with nirmatrelvir/ritonavir are limited due to the clinical illness, the short window for intervention, and the related difficulty of implementing clinical monitoring or dosage adjustment of the comedication. Pragmatic options are largely confined to preemptive or symptom‐driven pausing of the comedication or managing any additional risk through counseling. This review summarizes the effects of ritonavir on drug disposition (i.e., metabolizing enzymes and transporters) and discusses factors determining the likelihood of having a clinically significant DDI. Furthermore, it provides a comprehensive list of comedications likely to be used in COVID‐19 patients which are categorized according to their potential DDI risk with nirmatrelvir/ritonavir. It also discusses recommendations for the management of DDIs which balance the risk of harm from DDIs with a short course of ritonavir, against unnecessary denial of nirmatrelvir/ritonavir treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 2,987
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118542 · Cited by 2,323 · cited 1×
“Nirmatrelvir/ritonavir at an oral dose of 300/100 mg twice daily for 5 days reduced the risk of COVID19 related hospitalization and death within 28 days by 89% when compared with a placebo group when treatment was started within 3 days of COVID- 19 symptoms onset.(1) Due to the use of ritonavir, nirmatrelvir/ritonavir…”
MethodHuman P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
Mueck, W., Kubitza, D., & Becka, M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12075 · Cited by 371
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P. H., Mauri, L., et al. (2018) · Open Access CRIS of the University of Bern · doi:10.7892/boris.107408 · Cited by 230
Katzenmaier, S., Markert, C., Riedel, K.-D., Burhenne, J., Haefeli, W. E., & Mikus, G. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.164 · Cited by 135
Marzolini, C., Gibbons, S., Khoo, S., & Back, D. J. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw032 · Cited by 128
Self-citationPopulation pharmacokinetics of long-term oral amiodarone therapy
Pollak, P. T. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.107047 · Cited by 102
Clinically relevant drug interactions with multikinase inhibitors: a review
Hussaarts, K. G. A. M., Veerman, G., Jansman, F. G. A., van Gelder, T., Mathijssen, R. H. J., & van Leeuwen, R. W. F. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918818347 · Cited by 101
Salerno, D. M., Jennings, D. L., Lange, N. W., Kovac, D., Shertel, T., Chen, J. K., Hedvat, J., Scheffert, J. L., Brown, R. S., & Pereira, M. R. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17027 · Cited by 88
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Metadata
- Authors
- Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., Pozniak, A., Boffito, M., Waters, L., Burger, D., Back, D. J., & Khoo, S.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2022-06-07
- Volume
- 112
- Issue
- 6
- Pages
- 1191-1200
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W4280510519
- Cited by
- 262
- References
- 30
- FWCI
- 47.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. https://app.cochat.ai/papers/10.1002/cpt.2646
- The paper
- Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., Pozniak, A., Boffito, M., Waters, L., Burger, D., Back, D. J., & Khoo, S. (2022). Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.2646
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.